semaglutide for ckd Novo Nordisk's Ozempic excels in diabetes, kidney disease trial FLOWing with the SemagluTIDE —

110 RomeoB.ChouchaW.FossatiP.RotgeJ

The psychological stress of lifestyle modification, body image concerns, and the physical demands of significant weight loss can all impact mental health independently of medication effects

GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) reduce appetite, slow digestion, and support blood sugar regulation

If you want a doctor and dietitian working together, Mochi could be the best fit

Doses studied in tesofensine clinical trials Dose 0.25 mg daily Trial context Phase 2 (Astrup 2008) and Phase 3 (Mexico) Duration 24 weeks Outcome reported About 6-7% placebo-subtracted weight loss Dose 0.5 mg daily Trial context Phase 2 (Astrup 2008) and Phase 3 (Mexico) Duration 24 weeks Outcome reported About 9-10% placebo-subtracted weight loss Dose 1.0 mg daily Trial context Phase 2 only (Astrup 2008) Duration 24 weeks Outcome reported Highest weight loss but more blood pressure issues and dropouts